Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
| Consumer Staples Distribution & Retail Industry | Consumer Staples Sector | Robert Mauch CEO | XFRA Exchange | 03073E105 CUSIP |
| US Country | 49,000 Employees | 14 Aug 2026 Last Dividend | 16 Jun 2009 Last Split | 4 Apr 1995 IPO Date |
Cencora, Inc., previously known as AmerisourceBergen Corporation, is a global leader in healthcare solutions, with a focus on improving patient outcomes through the efficient distribution and commercialization of pharmaceuticals and healthcare-related products. Established in 2001 and headquartered in Conshohocken, Pennsylvania, Cencora has expanded its reach by providing a wide range of services to various healthcare providers, including acute care hospitals, retail pharmacies, mail order pharmacies, and specialists across numerous disease states. The company's commitment to offering comprehensive supply chain management services, specialized software, and consulting services underscores its integral role in the healthcare sector. Through its U.S. Healthcare Solutions and International Healthcare Solutions segments, Cencora, Inc. addresses the nuanced needs of its global client base, delivering tailored services that encompass distribution, commercialization, logistics, and much more.